Journal
MOLECULES
Volume 25, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/molecules25030745
Keywords
antibodies; antibody drug conjugate; API; biologics; chemical entities; drug discovery; fluorine-based drugs; natural products; oligonucleotides; peptides; pyrazoles; TIDES; small molecules
Funding
- National Research Foundation (NRF)
- University of KwaZulu-Natal (South Africa)
- MINECO [RTI2018-093831-B-100]
- Generalitat de Catalunya (Spain) [2017 SGR 1439]
Ask authors/readers for more resources
During 2019, the US Food and Drug Administration (FDA) approved 48 new drugs (38 New Chemical Entities and 10 Biologics). Although this figure is slightly lower than that registered in 2018 (59 divided between 42 New Chemical Entities and 17 Biologics), a year that broke a record with respect to new drugs approved by this agency, it builds on the trend initiated in 2017, when 46 drugs were approved. Of note, three antibody drug conjugates, three peptides, and two oligonucleotides were approved in 2019. This report analyzes the 48 new drugs of the class of 2019 from a strictly chemical perspective. The classification, which was carried out on the basis of chemical structure, includes the following: Biologics (antibody drug conjugates, antibodies, and proteins); TIDES (peptide and oligonucleotides); drug combinations; natural products; and small molecules.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available